암 진단 분야 인공지능(AI) 시장 : 예측(2024-2029년)

The AI in cancer diagnostics market is expected to grow at a CAGR of 35.54%, reaching a market size of US$9,105.634 million in 2029 from US$1,990.572 million in 2024.

The AI in the cancer diagnostics market is expanding rapidly as artificial intelligence technologies revolutionize cancer diagnostics. AI algorithms analyze massive volumes of patient data, such as medical pictures, genetic data, and clinical records, to help in cancer identification, classification, and prognosis. AI systems help in detecting anomalies and patterns in medical images, making use of artificial intelligence and machine learning; this approach helps in the early detection of cancer and improves patient outcomes.

Moreover, integrating AI in cancer diagnostics helps improve precision, eliminates diagnostic mistakes, leaves no room for misdiagnosis, and provides personalized therapy. In the projected period, with increasing cancer cases and growing demand for personalized solutions for treating cancer, it is expected to offer the market for AI in cancer diagnostics an enormous opportunity to expand.

AI in Cancer Diagnostics Market Drivers

• Advancements in Artificial Intelligence Technologies Enhance the AI in Cancer Diagnostics Market Growth.

AI developments have the potential to revolutionize cancer diagnostics by increasing accuracy, efficiency, and early detection rates, ultimately leading to better patient outcomes and personalized treatment methods.

• Integration of Multi-modal Data for Comprehensive Analysis in AI in Cancer Diagnostics Market.

Integrating multimodal data for thorough analysis has emerged as a key development in cancer diagnoses. This enables a more thorough picture of the disease, allowing doctors to make educated decisions and design personalized treatment strategies for cancer patients.

AI in Cancer Diagnostics Market Geographical Outlook

• North America is expected to hold a significant share in the AI in Cancer Diagnostics Market.

Geographically, North America is considered the industry leader in AI in the cancer diagnostics market. Several factors contribute to this. North America has significant healthcare infrastructure in place; the headquarters of most key AI companies are located within the region, and it carries a strong emphasis on cancer research and development. There are also extensive networks among healthcare institutions, research centers, and technology businesses in the region, which stir innovation and further the advancement of AI-based cancer diagnostics. North America also has a positive regulatory framework, allowing AI technologies to be adopted in diagnostics more easily.

In addition, there is much potential for regional AI in the cancer diagnostics market due to the large number of patients, high healthcare spending, and permissive reimbursement conditions in the region. On the other hand, tremendous improvements continue to be experienced in the AI in cancer diagnostics market from other parts of the world, including Europe and Asia Pacific.

Reasons for buying this report:-

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data & forecasts from 2022 to 2029
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

AI in Cancer Diagnostics market is segmented and analyzed as follows:

By Cancer Type

• Breast Cancer
• Lung Cancer
• Prostate Cancer
• Colorectal Cancer
• Skin Cancer
• Others

By Application

• Tumor Detection and Classification
• Treatment Planning
• Image Analysis
• Genomic Analysis
• Others

By End-User

• Hospitals And Clinics
• Diagnostic Centers
• Research Institutes
• Others

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Italy
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Taiwan
• Others

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Market Overview
• 1.2. Market Definition
• 1.3. Scope of the Study
• 1.4. Market Segmentation
• 1.5. Currency
• 1.6. Assumptions
• 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

• 2.1. Research Data
• 2.2. Sources
• 2.3. Research Design

3. EXECUTIVE SUMMARY

• 3.1. Research Highlights

4. MARKET DYNAMICS

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porters Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis

5. AI IN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE

• 5.1. Introduction
• 5.2. BREAST CANCER
• 5.3. LUNG CANCER
• 5.4. PROSTATE CANCER
• 5.5. COLORECTAL CANCER
• 5.6. SKIN CANCER
• 5.7. OTHERS

6. AI IN CANCER DIAGNOSTICS MARKET, BY APPLICATION

• 6.1. Introduction
• 6.2. TUMOR DETECTION AND CLASSIFICATION
• 6.3. TREATMENT PLANNING
• 6.4. IMAGE ANALYSIS
• 6.5. GENOMIC ANALYSIS
• 6.6. OTHERS

7. AI IN CANCER DIAGNOSTICS MARKET, BY END-USER

• 7.1. Introduction
• 7.2. HOSPITALS AND CLINICS
• 7.3. DIAGNOSTIC CENTERS
• 7.4. RESEARCH INSTITUTES
• 7.5. OTHERS

8. AI IN CANCER DIAGNOSTICS MARKET, BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. United States
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. United Kingdom
  • 8.4.2. Germany
  • 8.4.3. France
  • 8.4.4. Italy
  • 8.4.5. Spain
  • 8.4.6. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. Japan
  • 8.6.2. China
  • 8.6.3. India
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Taiwan
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Emerging Players and Market Lucrativeness
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

• 10.1. GOOGLE LLC (ALPHABET INC.)
• 10.2. IBM CORPORATION
• 10.3. MICROSOFT CORPORATION
• 10.4. PAIGE.AI, INC.
• 10.5. TEMPUS LABS, INC.
• 10.6. PATHAI, INC.
• 10.7. INSPIRATA, INC.
• 10.8. PROSCIA INC.
• 10.9. IBEX MEDICAL ANALYTICS LTD.
• 10.10. ZEBRA MEDICAL VISION LTD.